Oncology News | pharmaphorum

News

Arcus preps more phase 3 trials for TIGIT antibody, as Gilea...

Armed with a positive mid-stage trial readout in lung cancer, Arcus Biosciences will expand a phase 3 programme for domvanalimab, its anti-TIGIT antibody.

News

AbbVie jumps on the BCMA train, opting into TeneoOne buy

After dipping its toe into the BCMA water with an option to codevelop a bispecific antibody developed by TeneoOne, AbbVie has gone one step further – agreeing to buy the drug and the compan

News

AZ, HutchMed's savolitinib gets 1st approval in China for NS...

AstraZeneca and HutchMed have claimed their first approval – in China – for cMET inhibitor savolitinib as a treatment of patients with a form of non-small cell lung cancer.

News

In a class first, Merck's Keytruda extends survival in cervi...

Merck & Co's Keytruda has become the first checkpoint inhibitor to help patients with advanced cervical cancer live longer when used as alongside standard first-line drugs.

News

BioNTech takes its first cancer vaccine into phase 2

It would be easy to forget that back in 2019, BioNTech was an early-stage biotech firmly focused on cancer vaccines, before being catapulted onto the world-stage with its COVID-19 shot.

News

BMS pays $650m upfront for Eisai's first ADC candidate for c...

Japan's Eisai has hit the jackpot with its first ever antibody-drug conjugate (ADC) drug candidate, attracting a licensing deal from Bristol-Myers Squibb that could top out at more than $3.

Arcus preps more phase 3 trials for TIGIT antibody, as Gilea...

AbbVie jumps on the BCMA train, opting into TeneoOne buy

AZ, HutchMed's savolitinib gets 1st approval in China for NS...

In a class first, Merck's Keytruda extends survival in cervi...

BioNTech takes its first cancer vaccine into phase 2

BMS pays $650m upfront for Eisai's first ADC candidate for c...

NICE recommends wider use of Biogen MS drug via NHS

How to meet your physicians where they are online

News

Editor's Picks